An Attempt at a Molecular Prediction of Metastasis in Patients with Primary Cutaneous Melanoma

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Gschaider, Melanie ^a   Neumann, Friederike ^b   Peters, Bettina ^c   Lenz, Florian ^b   Cibena, Michael ^b   Goiser, Malgorzata ^a   Wolf, Ingrid ^d   Wenzel, Jörg ^e   Mauch, Cornelia ^f   Schreiner, Wolfgang ^b   Wagner, Stephan N ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c GERMAN AEROSPACE CENTER DLR   (Germany)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e UNIVERSITY OF BONN   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CARCINOGENESIS; COHORT ANALYSIS; CUTANEOUS MELANOMA; DIAGNOSTIC VALUE; ENA GENE; EVL GENE; FEMALE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC DATABASE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; MOLECULAR DIAGNOSIS; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIMARY TUMOR; SERIAL ANALYSIS OF GENE EXPRESSION; SURVIVAL PREDICTION; VALIDATION PROCESS;

GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEDICAL ONCOLOGY; MELANOMA; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; SKIN NEOPLASMS;

EID: 84869112904     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049865     Document Type: Article

References (59)

1. Miller AJ, Mihm MC Jr, (2006) Melanoma. N Engl J Med 355: 51-65.
2. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, et al. (2007) Cancer Incidence in Five Continents. Vol. IX. [Internet]. IARC Scientific Publications No. 160. Lyon, France: International Agency for Research on Cancer.
3. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA, (2009) Increasing burden of melanoma in the United States. J Invest Dermatol 129: 1666-1674.
4. Lotze MT, Dallal RM, Kirkwood JM, Flickinger JC (2001) Cutaneous melanoma. In: HS DeVita VT Jr RS, editor. Cancer: principles & practice of oncology. Philadelphia, PA: Lippincott Williams & Wilkins. p.2012-69.
5. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199-6206.
6. Breslow A, (1970) Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172: 902-908.
7. Elder DE, Gimotty PA, Guerry D, (2005) Cutaneous melanoma: estimating survival and recurrence risk based on histopathologic features. Dermatol Ther 18: 369-385.
8. Tsao H, Atkins MB, Sober AJ, (2004) Management of cutaneous melanoma. N Engl J Med 351: 998-1012.
9. Gimotty PA, Botbyl J, Soong SJ, Guerry D, (2005) A population-based validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 23: 8065-8075.
10. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, et al. (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3622-3634.
11. Mandruzzato S, Callegaro A, Turcatel G, Francescato S, Montesco MC, et al. (2006) A gene expression signature associated with survival in metastatic melanoma. J Transl Med 4: 50.
12. Alonso SR, Tracey L, Ortiz P, Perez-Gomez B, Palacios J, et al. (2007) A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res 67: 3450-3460.
13. John T, Black MA, Toro TT, Leader D, Gedye CA, et al. (2008) Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res 14: 5173-5180.
14. Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, et al. (2009) Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A 106: 20429-20434.
15. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, et al. (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98: 472-482.
16. Kabbarah O, Nogueira C, Feng B, Nazarian RM, Bosenberg M, et al. (2010) Integrative genome comparison of primary and metastatic melanomas. PLoS One 5: e10770.
17. Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, Mansuet-Lupo A, et al. (2008) High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 27: 565-573.
18. Laurent C, Valet F, Planque N, Silveri L, Maacha S, et al. (2011) High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. Cancer Res 71: 666-674.
19. Petrausch U, Martus P, Tonnies H, Bechrakis NE, Lenze D, et al. (2008) Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond) 22: 997-1007.
20. Worley LA, Onken MD, Person E, Robirds D, Branson J, et al. (2007) Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res 13: 1466-1471.
21. Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, et al. (2008) Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res 6: 760-769.
22. Brunner G, Reitz M, Schwipper V, Tilkorn H, Lippold A, et al. (2008) Increased expression of the tumor suppressor PLZF is a continuous predictor of long-term survival in malignant melanoma patients. Cancer Biother Radiopharm 23: 451-459.
23. Conway C, Mitra A, Jewell R, Randerson-Moor J, Lobo S, et al. (2009) Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 15: 6939-6946.
24. Jonsson G, Busch C, Knappskog S, Geisler J, Miletic H, et al. (2010) Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res 16: 3356-3367.
25. Allison DB, Cui X, Page GP, Sabripour M, (2006) Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 7: 55-65.
26. Dupuy A, Simon RM, (2007) Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 99: 147-157.
27. Schramm SJ, Mann GJ, (2011) Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Mol Cancer Ther 10: 1520-1528.
28. Schramm SJ, Campain AE, Scolyer RA, Yang YH, Mann GJ, (2012) Review and cross-validation of gene expression signatures and melanoma prognosis. J Invest Dermatol 132: 274-283.
29. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2: 416-422.
30. Gould Rothberg BE, Bracken MB, Rimm DL, (2009) Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 101: 452-474.
31. Wenzel J, Peters B, Zahn S, Birth M, Hofmann K, et al. (2008) Gene expression profiling of lichen planus reflects CXCL9+-mediated inflammation and distinguishes this disease from atopic dermatitis and psoriasis. J Invest Dermatol 128: 67-78.
32. Wenzel J, Tomiuk S, Zahn S, Kusters D, Vahsen A, et al. (2008) Transcriptional profiling identifies an interferon-associated host immune response in invasive squamous cell carcinoma of the skin. Int J Cancer 123: 2605-2615.
33. Chalifa-Caspi V, Yanai I, Ophir R, Rosen N, Shmoish M, et al. (2004) GeneAnnot: comprehensive two-way linking between oligonucleotide array probesets and GeneCards genes. Bioinformatics 20: 1457-1458.
34. Kashani-Sabet M, Venna S, Nosrati M, Rangel J, Sucker A, et al. (2009) A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res 15: 6987-6992.
35. Mallett S, Timmer A, Sauerbrei W, Altman DG, (2010) Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. Br J Cancer 102: 173-180.
36. Kay R, Rosten PM, Humphries RK, (1991) CD24, a signal transducer modulating B cell activation responses, is a very short peptide with a glycosyl phosphatidylinositol membrane anchor. J Immunol 147: 1412-1416.
37. Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, et al. (1997) CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 89: 3385-3395.
38. Jaggupilli A, Elkord E, (2012) Significance of CD44 and CD24 as Cancer Stem Cell Markers: An Enduring Ambiguity. Clin Dev Immunol 2012: 708036 In press.
39. Kristiansen G, Sammar M, Altevogt P, (2004) Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 35: 255-262.
40. Dou J, Wen P, Hu W, Li Y, Wu Y, et al. (2009) Identifying tumor stem-like cells in mouse melanoma cell lines by analyzing the characteristics of side population cells. Cell Biol Int 33: 807-815.
41. Ehira N, Oshiumi H, Matsumoto M, Kondo T, Asaka M, et al. (2010) An embryo-specific expressing TGF-beta family protein, growth-differentiation factor 3 (GDF3), augments progression of B16 melanoma. J Exp Clin Cancer Res 29: 135.
42. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, et al. (2008) The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 1: 13.
43. Scott KL, Nogueira C, Heffernan TP, van Doorn R, Dhakal S, et al. (2011) Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell 20: 92-103.
44. Barzik M, Kotova TI, Higgs HN, Hazelwood L, Hanein D, et al. (2005) Ena/VASP proteins enhance actin polymerization in the presence of barbed end capping proteins. J Biol Chem 280: 28653-28662.
45. Hu LD, Zou HF, Zhan SX, Cao KM, (2008) EVL (Ena/VASP-like) expression is up-regulated in human breast cancer and its relative expression level is correlated with clinical stages. Oncol Rep 19: 1015-1020.
46. Toyoda A, Kawana H, Azuhata K, Yu J, Omata A, et al. (2009) Aberrant expression of human ortholog of mammalian enabled (hMena) in human colorectal carcinomas: implications for its role in tumor progression. Int J Oncol 34: 53-60.
47. Fiedler LR, Bachetti T, Leiper J, Zachary I, Chen L, et al. (2009) The ADMA/DDAH pathway regulates VEGF-mediated angiogenesis. Arterioscler Thromb Vasc Biol 29: 2117-2124.
48. Schick B, Praetorius M, Eigenthaler M, Jung V, Muller M, et al. (2004) Increased noise sensitivity and altered inner ear MENA distribution in VASP-/- mice. Cell Tissue Res 318: 493-502.
49. Hernandez-Varas P, Colo GP, Bartolome RA, Paterson A, Medrano-Fernandez I, et al. (2011) Rap1-GTP-interacting adaptor molecule (RIAM) protein controls invasion and growth of melanoma cells. J Biol Chem 286: 18492-18504.
50. Bae YH, Ding Z, Zou L, Wells A, Gertler F, et al. (2009) Loss of profilin-1 expression enhances breast cancer cell motility by Ena/VASP proteins. J Cell Physiol 219: 354-364.
51. Di Modugno F, Mottolese M, DeMonte L, Trono P, Balsamo M, et al. (2010) The cooperation between hMena overexpression and HER2 signalling in breast cancer. PLoS One 5: e15852.
52. Takaku M, Ueno H, Kurumizaka H, (2011) Biochemical analysis of the human ENA/VASP-family proteins, MENA, VASP and EVL, in homologous recombination. J Biochem 149: 721-729.
53. Kim CJ, Reintgen DS, Balch CM, (2002) The new melanoma staging system. Cancer Control 9: 9-15.
54. Bosio A, Knorr C, Janssen U, Gebel S, Haussmann HJ, et al. (2002) Kinetics of gene expression profiling in Swiss 3T3 cells exposed to aqueous extracts of cigarette smoke. Carcinogenesis 23: 741-748.
55. Pennartz S, Belvindrah R, Tomiuk S, Zimmer C, Hofmann K, et al. (2004) Purification of neuronal precursors from the adult mouse brain: comprehensive gene expression analysis provides new insights into the control of cell migration, differentiation, and homeostasis. Mol Cell Neurosci 25: 692-706.
56. Audic S, Claverie JM, (1997) The significance of digital gene expression profiles. Genome Res 7: 986-995.
57. Bolstad BM, Irizarry RA, Astrand M, Speed TP, (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193.
58. Cox DR, (1972) Regression models and life-tables. J R Stat Soc Series B Stat Methodol 34: 187-220.
59. Verweij PJ, Van Houwelingen HC, (1993) Cross-validation in survival analysis. Stat Med 12: 2305-2314.